These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 23099071)

  • 1. GAIN Act legislation: is it enough?
    Tillotson GS
    Lancet Infect Dis; 2012 Nov; 12(11):823-4. PubMed ID: 23099071
    [No Abstract]   [Full Text] [Related]  

  • 2. A call for antibiotic alternatives research.
    Stanton TB
    Trends Microbiol; 2013 Mar; 21(3):111-3. PubMed ID: 23473628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of new antibacterials: a laudable aim, but what is the value?
    Tillotson GS
    Clin Infect Dis; 2010 Sep; 51(6):752-3; author reply 754-5. PubMed ID: 20731567
    [No Abstract]   [Full Text] [Related]  

  • 4. Establishing a list of qualifying pathogens under the Food and Drug Administration Safety and Innovation Act. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2014 Jun; 79(108):32464-81. PubMed ID: 24908687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letter in response to the Infectious Diseases Society of America's 10 x '20 Initiative.
    Burgess DS; Slain D; Mohr J; Wong-Beringer A; Destache C; Suda K
    Clin Infect Dis; 2010 Sep; 51(6):753; author reply 754-5. PubMed ID: 20731568
    [No Abstract]   [Full Text] [Related]  

  • 6. New antibiotic development hailed as game changing.
    Kirby T
    Lancet Infect Dis; 2015 Mar; 15(3):271-2. PubMed ID: 25749231
    [No Abstract]   [Full Text] [Related]  

  • 7. Antibiotic bill doesn't GAIN enough ground.
    Ambrose PG
    Nat Med; 2011 Jul; 17(7):772. PubMed ID: 21738147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GAIN Act legislation to combat antimicrobial resistance: Where do we stand?
    Sfeir MM
    Infect Control Hosp Epidemiol; 2018 Dec; 39(12):1499-1500. PubMed ID: 30334503
    [No Abstract]   [Full Text] [Related]  

  • 9. Is the GAIN Act a turning point in new antibiotic discovery?
    Brown ED
    Can J Microbiol; 2013 Mar; 59(3):153-6. PubMed ID: 23540332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Target small firms for antibiotic innovation.
    Hwang TJ; Carpenter D; Kesselheim AS
    Science; 2014 May; 344(6187):967-9. PubMed ID: 24876477
    [No Abstract]   [Full Text] [Related]  

  • 11. Antibacterial resistance: is there a way out of the woods?
    Marra A
    Future Microbiol; 2011 Jul; 6(7):707-9. PubMed ID: 21797683
    [No Abstract]   [Full Text] [Related]  

  • 12. 2013 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2014 Feb; 13(2):85-9. PubMed ID: 24481294
    [No Abstract]   [Full Text] [Related]  

  • 13. 2012 and beyond: potential for the start of a second pre-antibiotic era?
    Appelbaum PC
    J Antimicrob Chemother; 2012 Sep; 67(9):2062-8. PubMed ID: 22687888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug development for neglected diseases - the trouble with FDA review vouchers.
    Kesselheim AS
    N Engl J Med; 2008 Nov; 359(19):1981-3. PubMed ID: 18987367
    [No Abstract]   [Full Text] [Related]  

  • 15. Health, Wealth, and the 21st Century Cures Act.
    Lo AW; Philipson TJ; von Eschenbach AC
    JAMA Oncol; 2016 Jan; 2(1):17-8. PubMed ID: 26513279
    [No Abstract]   [Full Text] [Related]  

  • 16. Testing times ahead.
    Goodrick S
    Lancet Neurol; 2015 Sep; 14(9):879. PubMed ID: 26293563
    [No Abstract]   [Full Text] [Related]  

  • 17. Antimicrobial resistance: no action today, no cure tomorrow.
    Sharma A
    Indian J Med Microbiol; 2011; 29(2):91-2. PubMed ID: 21654100
    [No Abstract]   [Full Text] [Related]  

  • 18. Questions about the 10 x '20 Initiative.
    Outterson K; Powers JH; Gould IM; Kesselheim AS
    Clin Infect Dis; 2010 Sep; 51(6):751-2; author reply 754-5. PubMed ID: 20731566
    [No Abstract]   [Full Text] [Related]  

  • 19. Regulatory watch: FDA guidance on co-developing investigational drugs.
    Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094
    [No Abstract]   [Full Text] [Related]  

  • 20. Raising the bar for market authorisation of new drugs.
    Naci H; Cylus J; Vandoros S; Sato A; Perampaladas K
    BMJ; 2012 Aug; 345():e4261. PubMed ID: 22872693
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.